Impact of Neoadjuvant Immunochemotherapy on Surgical Outcomes in Management of Early Triple‐Negative Breast Cancer
The Breast Journal · 2026-01 · 2026 (1)
DOI: 10.1155/tbj/5534220 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Breast Journal, online erschienen am 17.07.2026. Verfasst von Tamasine Khadrouche und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Claudius Regaud Institute-IUCT Oncopole, Toulouse, France. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Triple Negative Breast Neoplasms, Immunotherapy. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Triple‐negative breast cancer (TNBC) is an aggressive subtype with poor prognosis. Neoadjuvant immunochemotherapy (NAIC) combining chemotherapy and pembrolizumab is now standard for Stage II‐III TNBC. This study evaluates the impact of NAIC on surgical outcomes versus neoadjuvant chemotherapy (NAC).
Methods
A retrospective cohort study included 117 Stage II‐III TNBC patients treated with NAIC or NAC (October 2019–May 2023). Surgical complications, time to surgery, time to radiotherapy, and pathologic response were assessed. Complications were classified using the Clavien–Dindo scale; immune‐related adverse events (irAEs) followed the 2017 CTCAE criteria.
Results
Among 117 patients, 59 received NAIC and 58 NAC. Chemotherapy‐related adverse events were similar (NAIC: 78.0%, NAC: 75.9%). irAEs occurred in 50.8% of NAIC patients, with 8.5% experiencing severe irAEs. Surgical complications were more frequent in NAIC (27.1%) than NAC (17.2%), though not statistically significant; seroma was the most common. Delays > 12 weeks in initiating radiotherapy were more frequent in NAIC (10.7%) than NAC (0%).
Conclusion
NAIC did not significantly increase postoperative complications compared to NAC. However, irAEs and potential treatment delays warrant careful management. Despite these risks, NAIC remains a viable option for early TNBC with manageable surgical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgical Oncology, Claudius Regaud Institute-IUCT Oncopole, Toulouse, France.
- Biostatistics & Health Data Science Unit, Claudius Regaud Institute-IUCT Oncopole, Toulouse, France.
- Department of Surgical Oncology, University Hospital Center Toulouse-IUCT Oncopole, Toulouse, France.
- Department of Pathology, Claudius Regaud Institute-IUCT Oncopole, Toulouse, France.
- Department of Radiotherapy, Claudius Regaud Institute-IUCT Oncopole, Toulouse, France.
- Department of Medical Oncology, Claudius Regaud Institute - IUCT Oncopole, Toulouse, France.
ORCID-Profile: Gabrielle Selmes, Camille Franchet, Eleonora De Maio, Jean-Louis Lacaze, Eva Jouve
Zitieren
APA
Khadrouche, T., Morisseau, M., Selmes, G., Vaysse, C., Franchet, C., Massabeau, C., Ung, M., Maio, E., Lacaze, J. L., & Jouve, E. (2026). Impact of Neoadjuvant Immunochemotherapy on Surgical Outcomes in Management of Early Triple‐Negative Breast Cancer. The Breast Journal, 2026(1). https://doi.org/10.1155/tbj/5534220
Vancouver
Khadrouche T, Morisseau M, Selmes G, Vaysse C, Franchet C, Massabeau C, et al. Impact of Neoadjuvant Immunochemotherapy on Surgical Outcomes in Management of Early Triple‐Negative Breast Cancer. The Breast Journal. 2026;2026(1). doi:10.1155/tbj/5534220
BibTeX
@article{Khadrouche2026,
author = {Khadrouche, Tamasine and Morisseau, Mathilde and Selmes, Gabrielle and Vaysse, Charlotte and Franchet, Camille and Massabeau, Carole and Ung, Mony and Maio, Eleonora De and Lacaze, Jean-Louis and Jouve, Eva},
title = {Impact of Neoadjuvant Immunochemotherapy on Surgical Outcomes in Management of Early Triple‐Negative Breast Cancer},
journal = {The Breast Journal},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/tbj/5534220}
}
EUVIMED